RU2303038C2 - Азаиндолоксоуксусные производные пиперазины и фармацевтическая композиция на их основе - Google Patents
Азаиндолоксоуксусные производные пиперазины и фармацевтическая композиция на их основе Download PDFInfo
- Publication number
- RU2303038C2 RU2303038C2 RU2003127077/04A RU2003127077A RU2303038C2 RU 2303038 C2 RU2303038 C2 RU 2303038C2 RU 2003127077/04 A RU2003127077/04 A RU 2003127077/04A RU 2003127077 A RU2003127077 A RU 2003127077A RU 2303038 C2 RU2303038 C2 RU 2303038C2
- Authority
- RU
- Russia
- Prior art keywords
- group
- alkyl
- ome
- heteroaryl
- hydrogen
- Prior art date
Links
- 0 *C(C(c1c[n]c2c1ccnc2Cl)=O)=O Chemical compound *C(C(c1c[n]c2c1ccnc2Cl)=O)=O 0.000 description 53
- TWGNOYAGHYUFFR-UHFFFAOYSA-N Cc1cncnc1 Chemical compound Cc1cncnc1 TWGNOYAGHYUFFR-UHFFFAOYSA-N 0.000 description 2
- USFVXCTXPRQVQM-UHFFFAOYSA-N CC(Nc1ncc(C)nc1)=O Chemical compound CC(Nc1ncc(C)nc1)=O USFVXCTXPRQVQM-UHFFFAOYSA-N 0.000 description 1
- NCONCLVEVRMXHN-UHFFFAOYSA-N CC(c1ccc(-c2ccnc3c2[nH]cc3C(C(N(CC2)CCN2C(c2ccccc2)=O)=O)=O)[s]1)=O Chemical compound CC(c1ccc(-c2ccnc3c2[nH]cc3C(C(N(CC2)CCN2C(c2ccccc2)=O)=O)=O)[s]1)=O NCONCLVEVRMXHN-UHFFFAOYSA-N 0.000 description 1
- WXAYHPGWXNGMPP-UHFFFAOYSA-N CCC(C)C1SC(c(c2c3c(C(C(N(CC4)CCN4C(c4ccccc4)=O)=O)=O)c[nH]2)ncc3OC)=CN1 Chemical compound CCC(C)C1SC(c(c2c3c(C(C(N(CC4)CCN4C(c4ccccc4)=O)=O)=O)c[nH]2)ncc3OC)=CN1 WXAYHPGWXNGMPP-UHFFFAOYSA-N 0.000 description 1
- NYMYGNLCILQUMT-UHFFFAOYSA-N CN(C)c(nc1)ncc1Br Chemical compound CN(C)c(nc1)ncc1Br NYMYGNLCILQUMT-UHFFFAOYSA-N 0.000 description 1
- WMUHXFDYJJVMNX-UHFFFAOYSA-N CNc(c(OC)n1)ncc1Br Chemical compound CNc(c(OC)n1)ncc1Br WMUHXFDYJJVMNX-UHFFFAOYSA-N 0.000 description 1
- QAELEPITYBQINV-UHFFFAOYSA-N COc(c1c2[nH]cc1C(C(N(CC1)CCN1C(c1ccccc1)=O)=O)=O)cnc2-c(cn1)ccc1OC Chemical compound COc(c1c2[nH]cc1C(C(N(CC1)CCN1C(c1ccccc1)=O)=O)=O)cnc2-c(cn1)ccc1OC QAELEPITYBQINV-UHFFFAOYSA-N 0.000 description 1
- ZJCMITYMWSVXFX-UHFFFAOYSA-N COc(c1c2[nH]cc1C(C(N(CC1)CCN1C(c1ccccc1)=O)=O)=O)cnc2-c(nc1)cnc1N Chemical compound COc(c1c2[nH]cc1C(C(N(CC1)CCN1C(c1ccccc1)=O)=O)=O)cnc2-c(nc1)cnc1N ZJCMITYMWSVXFX-UHFFFAOYSA-N 0.000 description 1
- NVGMWTPYPRAGAE-UHFFFAOYSA-N COc(c1c2[nH]cc1C(C(N(CC1)CCN1C(c1ccccc1)=O)=O)=O)cnc2-c(nc1OC)cnc1N Chemical compound COc(c1c2[nH]cc1C(C(N(CC1)CCN1C(c1ccccc1)=O)=O)=O)cnc2-c(nc1OC)cnc1N NVGMWTPYPRAGAE-UHFFFAOYSA-N 0.000 description 1
- GNGDTVKVNBHXGC-UHFFFAOYSA-N COc(c1c2[nH]cc1C(C(N(CC1)CCN1C(c1ccccc1)=O)=O)=O)cnc2-c1cnncc1 Chemical compound COc(c1c2[nH]cc1C(C(N(CC1)CCN1C(c1ccccc1)=O)=O)=O)cnc2-c1cnncc1 GNGDTVKVNBHXGC-UHFFFAOYSA-N 0.000 description 1
- QAWNCMZMQJMEET-UHFFFAOYSA-N COc(c1c2[nH]cc1C(C(N(CC1)CCN1C(c1ccccc1)=O)=O)=O)cnc2-c1ncncc1 Chemical compound COc(c1c2[nH]cc1C(C(N(CC1)CCN1C(c1ccccc1)=O)=O)=O)cnc2-c1ncncc1 QAWNCMZMQJMEET-UHFFFAOYSA-N 0.000 description 1
- XBJLKXOOHLLTPG-UHFFFAOYSA-N COc(nn1)ccc1Cl Chemical compound COc(nn1)ccc1Cl XBJLKXOOHLLTPG-UHFFFAOYSA-N 0.000 description 1
- IHIVVXCQCAUAJE-UHFFFAOYSA-N COc1cnc(-c2ccc[s]2)c2c1c(C(C(N(CC1)CCN1C(c1ccccc1)=O)=O)=O)c[nH]2 Chemical compound COc1cnc(-c2ccc[s]2)c2c1c(C(C(N(CC1)CCN1C(c1ccccc1)=O)=O)=O)c[nH]2 IHIVVXCQCAUAJE-UHFFFAOYSA-N 0.000 description 1
- PBVPTXUMFKYJGY-UHFFFAOYSA-N COc1cnc(-c2cnc(SC)[s]2)c2c1c(C(C(N(CC1)CCN1C(c1ccccc1)=O)=O)=O)c[nH]2 Chemical compound COc1cnc(-c2cnc(SC)[s]2)c2c1c(C(C(N(CC1)CCN1C(c1ccccc1)=O)=O)=O)c[nH]2 PBVPTXUMFKYJGY-UHFFFAOYSA-N 0.000 description 1
- ARXQNJSILBZKTP-CYBMUJFWSA-N C[C@H](CN(CC1)C(c2ccccc2)=O)N1C(C(c1c[nH]c(c(C(NC)=O)c2)c1nc2Cl)=O)=O Chemical compound C[C@H](CN(CC1)C(c2ccccc2)=O)N1C(C(c1c[nH]c(c(C(NC)=O)c2)c1nc2Cl)=O)=O ARXQNJSILBZKTP-CYBMUJFWSA-N 0.000 description 1
- ZCBZCFQDRLIDGS-MRXNPFEDSA-N C[C@H](CN(CC1)C(c2ccccc2)=O)N1C(C(c1c[nH]c2c1ccnc2-c1cncnc1)=O)=O Chemical compound C[C@H](CN(CC1)C(c2ccccc2)=O)N1C(C(c1c[nH]c2c1ccnc2-c1cncnc1)=O)=O ZCBZCFQDRLIDGS-MRXNPFEDSA-N 0.000 description 1
- MFTHLRMYUXPSQB-OAHLLOKOSA-O C[C@H](CN(CC1)C(c2ccccc2)=O)N1C(C(c1c[nH]c2c1ccnc2-c1nc(O)c[n+](O)c1)=O)=O Chemical compound C[C@H](CN(CC1)C(c2ccccc2)=O)N1C(C(c1c[nH]c2c1ccnc2-c1nc(O)c[n+](O)c1)=O)=O MFTHLRMYUXPSQB-OAHLLOKOSA-O 0.000 description 1
- KWVJZEVZZJJHKV-GOSISDBHSA-N C[C@H](CN(CC1)C(c2ccccc2)=O)N1C(C(c1c[nH]c2c1nccc2C(NCc1ccc(C(F)(F)F)cc1)=O)=O)=O Chemical compound C[C@H](CN(CC1)C(c2ccccc2)=O)N1C(C(c1c[nH]c2c1nccc2C(NCc1ccc(C(F)(F)F)cc1)=O)=O)=O KWVJZEVZZJJHKV-GOSISDBHSA-N 0.000 description 1
- SOHMZGMHXUQHGE-UHFFFAOYSA-N Cc(cn1)ccc1O Chemical compound Cc(cn1)ccc1O SOHMZGMHXUQHGE-UHFFFAOYSA-N 0.000 description 1
- RONZKCOYMGOIJL-UHFFFAOYSA-N Cc(nc1)cnc1NC(NC)=O Chemical compound Cc(nc1)cnc1NC(NC)=O RONZKCOYMGOIJL-UHFFFAOYSA-N 0.000 description 1
- WNQORAUJIPRIRG-UHFFFAOYSA-N Cc1cnc(SC)[s]1 Chemical compound Cc1cnc(SC)[s]1 WNQORAUJIPRIRG-UHFFFAOYSA-N 0.000 description 1
- CAWHJQAVHZEVTJ-UHFFFAOYSA-N Cc1cnccn1 Chemical compound Cc1cnccn1 CAWHJQAVHZEVTJ-UHFFFAOYSA-N 0.000 description 1
- XZGLNCKSNVGDNX-UHFFFAOYSA-N Cc1n[nH]nn1 Chemical compound Cc1n[nH]nn1 XZGLNCKSNVGDNX-UHFFFAOYSA-N 0.000 description 1
- DJKUIGPCSNRFRK-UHFFFAOYSA-N Cc1n[s]c(N)n1 Chemical compound Cc1n[s]c(N)n1 DJKUIGPCSNRFRK-UHFFFAOYSA-N 0.000 description 1
- JOYXUTVJYBTNQW-UHFFFAOYSA-N Cc1nc(F)c(N)[n]1C Chemical compound Cc1nc(F)c(N)[n]1C JOYXUTVJYBTNQW-UHFFFAOYSA-N 0.000 description 1
- TUHNVVKXNJNRHE-UHFFFAOYSA-N Cc1nc(O)n[o]1 Chemical compound Cc1nc(O)n[o]1 TUHNVVKXNJNRHE-UHFFFAOYSA-N 0.000 description 1
- YVDWFZIVIIKYBQ-UHFFFAOYSA-N Cc1nnc(C)[o]1 Chemical compound Cc1nnc(C)[o]1 YVDWFZIVIIKYBQ-UHFFFAOYSA-N 0.000 description 1
- ZMSIFDIKIXVLDF-UHFFFAOYSA-N Cc1nnc[o]1 Chemical compound Cc1nnc[o]1 ZMSIFDIKIXVLDF-UHFFFAOYSA-N 0.000 description 1
- ZBEYLQBHTDNDDR-UHFFFAOYSA-N Clc1ccnc2c1[nH]cc2 Chemical compound Clc1ccnc2c1[nH]cc2 ZBEYLQBHTDNDDR-UHFFFAOYSA-N 0.000 description 1
- MLCNOCRGSBCAGH-UHFFFAOYSA-N Clc1nccnc1Cl Chemical compound Clc1nccnc1Cl MLCNOCRGSBCAGH-UHFFFAOYSA-N 0.000 description 1
- NPYSOFQIUAMBDI-UHFFFAOYSA-N O=C(C(N(CC1)CCN1C(c1ccccc1)=O)=O)c1c[nH]c2c1c(F)cnc2-c1cncnc1 Chemical compound O=C(C(N(CC1)CCN1C(c1ccccc1)=O)=O)c1c[nH]c2c1c(F)cnc2-c1cncnc1 NPYSOFQIUAMBDI-UHFFFAOYSA-N 0.000 description 1
- RPKDUMXASQOKGD-UHFFFAOYSA-N O=C(C(N(CC1)CCN1C(c1ccccc1)=O)=O)c1c[nH]c2c1c(F)cnc2-c1cnncc1 Chemical compound O=C(C(N(CC1)CCN1C(c1ccccc1)=O)=O)c1c[nH]c2c1c(F)cnc2-c1cnncc1 RPKDUMXASQOKGD-UHFFFAOYSA-N 0.000 description 1
- UPJYJMDYEJZWEQ-UHFFFAOYSA-N OC(C(c1c[nH]c2c1c(F)cnc2-c1cnc[o]1)=O)=O Chemical compound OC(C(c1c[nH]c2c1c(F)cnc2-c1cnc[o]1)=O)=O UPJYJMDYEJZWEQ-UHFFFAOYSA-N 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N c1ccnnc1 Chemical compound c1ccnnc1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26618301P | 2001-02-02 | 2001-02-02 | |
| US60/266,183 | 2001-02-02 | ||
| US31440601P | 2001-08-23 | 2001-08-23 | |
| US60/314,406 | 2001-08-23 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2003127077A RU2003127077A (ru) | 2005-03-20 |
| RU2303038C2 true RU2303038C2 (ru) | 2007-07-20 |
Family
ID=26951680
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2003127077/04A RU2303038C2 (ru) | 2001-02-02 | 2002-01-02 | Азаиндолоксоуксусные производные пиперазины и фармацевтическая композиция на их основе |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US20030069266A1 (enExample) |
| EP (1) | EP1363705B9 (enExample) |
| JP (1) | JP4328527B2 (enExample) |
| KR (1) | KR20030079979A (enExample) |
| CN (1) | CN100384423C (enExample) |
| AR (1) | AR034292A1 (enExample) |
| BG (1) | BG66359B1 (enExample) |
| BR (1) | BRPI0206636B8 (enExample) |
| CA (1) | CA2437524C (enExample) |
| CY (1) | CY1113194T1 (enExample) |
| CZ (1) | CZ303750B6 (enExample) |
| DK (1) | DK1363705T3 (enExample) |
| EE (1) | EE05424B1 (enExample) |
| ES (1) | ES2387981T3 (enExample) |
| HR (1) | HRP20030694A2 (enExample) |
| HU (1) | HU229305B1 (enExample) |
| IL (2) | IL157029A0 (enExample) |
| IS (1) | IS2912B (enExample) |
| MX (1) | MXPA03006939A (enExample) |
| MY (1) | MY137480A (enExample) |
| NO (1) | NO326510B1 (enExample) |
| NZ (1) | NZ527193A (enExample) |
| PE (1) | PE20020855A1 (enExample) |
| PL (1) | PL364279A1 (enExample) |
| PT (1) | PT1363705E (enExample) |
| RS (1) | RS52489B (enExample) |
| RU (1) | RU2303038C2 (enExample) |
| SK (1) | SK287900B6 (enExample) |
| TW (1) | TWI318978B (enExample) |
| WO (1) | WO2002062423A1 (enExample) |
| ZA (1) | ZA200305885B (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6476034B2 (en) * | 2000-02-22 | 2002-11-05 | Bristol-Myers Squibb Company | Antiviral azaindole derivatives |
| US20030207910A1 (en) * | 2001-02-02 | 2003-11-06 | Tao Wang | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
| US20040110785A1 (en) * | 2001-02-02 | 2004-06-10 | Tao Wang | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
| WO2003072028A2 (en) * | 2002-02-23 | 2003-09-04 | Bristol-Myers Squibb Company | Method of treating hiv infection by preventing interaction of cd4 and gp120 |
| US7348337B2 (en) | 2002-05-28 | 2008-03-25 | Bristol-Myers Squibb Company | Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides |
| US6900206B2 (en) | 2002-06-20 | 2005-05-31 | Bristol-Myers Squibb Company | Indole, azaindole and related heterocyclic sulfonylureido piperazine derivatives |
| ATE441417T1 (de) | 2002-12-20 | 2009-09-15 | Glaxo Group Ltd | Benzoädüazepinderivate für die behandlung von neurologischen krankheiten |
| US20050075364A1 (en) * | 2003-07-01 | 2005-04-07 | Kap-Sun Yeung | Indole, azaindole and related heterocyclic N-substituted piperazine derivatives |
| US20050124623A1 (en) * | 2003-11-26 | 2005-06-09 | Bender John A. | Diazaindole-dicarbonyl-piperazinyl antiviral agents |
| UA88297C2 (ru) * | 2004-03-15 | 2009-10-12 | Бристол-Майэрс Сквибб Компани | Пиперазиновые пролекарства и замещенные пиперидиновые антивирусные средства |
| US7745625B2 (en) | 2004-03-15 | 2010-06-29 | Bristol-Myers Squibb Company | Prodrugs of piperazine and substituted piperidine antiviral agents |
| US20050244458A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular neuropathies |
| JP2008501758A (ja) | 2004-06-09 | 2008-01-24 | グラクソ グループ リミテッド | ピロロピリジン誘導体 |
| US7642269B2 (en) | 2004-09-03 | 2010-01-05 | Yuhan Corporation | Pyrrolo[3,2-B]pyridine derivatives and processes for the preparation thereof |
| US20060100432A1 (en) * | 2004-11-09 | 2006-05-11 | Matiskella John D | Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione |
| US20060100209A1 (en) * | 2004-11-09 | 2006-05-11 | Chong-Hui Gu | Formulations of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione |
| US7183284B2 (en) * | 2004-12-29 | 2007-02-27 | Bristol-Myers Squibb Company | Aminium salts of 1,2,3-triazoles as prodrugs of drugs including antiviral agents |
| US7601715B2 (en) | 2005-06-22 | 2009-10-13 | Bristol-Myers Squibb Company | Process for preparing triazole substituted azaindoleoxoacetic piperazine derivatives and novel salt forms produced therein |
| US7396830B2 (en) * | 2005-10-04 | 2008-07-08 | Bristol-Myers Squibb Company | Piperazine amidines as antiviral agents |
| US7851476B2 (en) * | 2005-12-14 | 2010-12-14 | Bristol-Myers Squibb Company | Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine |
| US7807671B2 (en) * | 2006-04-25 | 2010-10-05 | Bristol-Myers Squibb Company | Diketo-piperazine and piperidine derivatives as antiviral agents |
| US7504399B2 (en) * | 2006-06-08 | 2009-03-17 | Bristol-Meyers Squibb Company | Piperazine enamines as antiviral agents |
| WO2008005910A2 (en) * | 2006-07-06 | 2008-01-10 | Bristol-Myers Squibb Company | Pyridone/hydroxypyridine 11-beta hydroxysteroid dehydrogenase type i inhibitors |
| CN101516877B (zh) * | 2006-09-22 | 2013-09-11 | 诺瓦提斯公司 | 杂环有机化合物 |
| US7960406B2 (en) | 2008-06-25 | 2011-06-14 | Bristol-Myers Squibb Company | Diketo substituted pyrrolo[2,3-c] pyridines |
| ES2389478T3 (es) | 2008-06-25 | 2012-10-26 | Bristol-Myers Squibb Company | Derivados de dicetopiperidina como inhibidores de la fijación del VIH |
| EP2601174B1 (en) | 2010-08-06 | 2014-11-26 | Bristol-Myers Squibb Company | Substituted indole and azaindole oxoacetyl piperazinamide derivatives |
| WO2012075235A1 (en) | 2010-12-02 | 2012-06-07 | Bristol-Myers Squibb Company | Alkyl amides as hiv attachment inhibitors |
| ES2636312T3 (es) | 2011-04-12 | 2017-10-05 | VIIV Healthcare UK (No.5) Limited | Derivados de tioamida, amidoxima y amidrazona como inhibidores de la fijación del VIH |
| WO2013033061A1 (en) | 2011-08-29 | 2013-03-07 | Bristol-Myers Squibb Company | Fused bicyclic diamine derivatives as hiv attachment inhibitors |
| US8664213B2 (en) | 2011-08-29 | 2014-03-04 | Bristol-Myers Squibb Company | Spiro bicyclic diamine derivatives as HIV attachment inhibitors |
| MX352320B (es) | 2012-02-08 | 2017-11-21 | Viiv Healthcare Uk No 4 Ltd | Metodos para la preparacion del compuesto profarmaco de piperazina inhibidor de la union de virus de inmunodeficiencia humana. |
| WO2013138436A1 (en) | 2012-03-14 | 2013-09-19 | Bristol-Myers Squibb Company | Cyclolic hydrazine derivatives as hiv attachment inhibitors |
| WO2014060381A1 (de) | 2012-10-18 | 2014-04-24 | Bayer Cropscience Ag | Heterocyclische verbindungen als schädlingsbekämpfungsmittel |
| CN104884449A (zh) | 2012-10-31 | 2015-09-02 | 拜尔农作物科学股份公司 | 作为害虫防治剂的新的杂环化合物 |
| WO2016004305A2 (en) | 2014-07-02 | 2016-01-07 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
| KR102932817B1 (ko) | 2019-06-19 | 2026-03-04 | 비브 헬스케어 유케이 (넘버5) 리미티드 | 인간 면역결핍 바이러스 복제의 억제제로서의 피리도[2,3-d]피리미딘 유도체 |
| US11862306B1 (en) | 2020-02-07 | 2024-01-02 | Cvs Pharmacy, Inc. | Customer health activity based system for secure communication and presentation of health information |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996011929A1 (en) * | 1994-10-12 | 1996-04-25 | Smithkline Beecham Plc | Biheteroaryl-carbonyl and carboxamide derivatives with 5ht 2c/2b antagonists activity |
| RU2099336C1 (ru) * | 1991-04-05 | 1997-12-20 | Лабораториос Дель Др.Эстеве, С.А. | Производные бензимидазола, способ их получения и фармацевтическая композиция на их основе, обладающая антигистаминной активностью |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5563142A (en) * | 1989-12-28 | 1996-10-08 | The Upjohn Company | Diaromatic substituted compounds as anti-HIV-1 agents |
| TW406075B (en) * | 1994-12-13 | 2000-09-21 | Upjohn Co | Alkyl substituted piperidinyl and piperazinyl anti-AIDS compounds |
| SK16482001A3 (sk) * | 1999-05-21 | 2002-04-04 | Scios Inc. | Indolové deriváty ako inhibítory p38 kinázy |
| US6469006B1 (en) * | 1999-06-15 | 2002-10-22 | Bristol-Myers Squibb Company | Antiviral indoleoxoacetyl piperazine derivatives |
| CA2382755A1 (en) * | 1999-07-28 | 2001-02-01 | Aventis Pharmaceuticals Products Inc. | Substituted oxoazaheterocyclyl compounds |
| EP1990343B1 (en) * | 1999-12-24 | 2012-04-04 | Aventis Pharma Limited | Azaindoles |
| US20020061892A1 (en) * | 2000-02-22 | 2002-05-23 | Tao Wang | Antiviral azaindole derivatives |
| WO2002004440A1 (en) * | 2000-07-10 | 2002-01-17 | Bristol-Myers Squibb Company | Composition and antiviral activity of substituted indoleoxoacetic piperazine derivatives |
| US6825201B2 (en) * | 2001-04-25 | 2004-11-30 | Bristol-Myers Squibb Company | Indole, azaindole and related heterocyclic amidopiperazine derivatives |
-
2002
- 2002-01-02 RU RU2003127077/04A patent/RU2303038C2/ru active
- 2002-01-02 EE EEP200300359A patent/EE05424B1/xx unknown
- 2002-01-02 SK SK959-2003A patent/SK287900B6/sk not_active IP Right Cessation
- 2002-01-02 JP JP2002562428A patent/JP4328527B2/ja not_active Expired - Lifetime
- 2002-01-02 HR HR20030694A patent/HRP20030694A2/hr not_active Application Discontinuation
- 2002-01-02 EP EP02707413A patent/EP1363705B9/en not_active Expired - Lifetime
- 2002-01-02 CZ CZ20032316A patent/CZ303750B6/cs not_active IP Right Cessation
- 2002-01-02 PL PL02364279A patent/PL364279A1/xx unknown
- 2002-01-02 RS YU60903A patent/RS52489B/sr unknown
- 2002-01-02 ES ES02707413T patent/ES2387981T3/es not_active Expired - Lifetime
- 2002-01-02 KR KR10-2003-7010208A patent/KR20030079979A/ko not_active Withdrawn
- 2002-01-02 BR BR0206636-0 patent/BRPI0206636B8/pt not_active IP Right Cessation
- 2002-01-02 MX MXPA03006939A patent/MXPA03006939A/es active IP Right Grant
- 2002-01-02 IL IL15702902A patent/IL157029A0/xx unknown
- 2002-01-02 PT PT02707413T patent/PT1363705E/pt unknown
- 2002-01-02 US US10/038,306 patent/US20030069266A1/en not_active Abandoned
- 2002-01-02 DK DK02707413.7T patent/DK1363705T3/da active
- 2002-01-02 WO PCT/US2002/000455 patent/WO2002062423A1/en not_active Ceased
- 2002-01-02 NZ NZ527193A patent/NZ527193A/en not_active IP Right Cessation
- 2002-01-02 CN CNB028078268A patent/CN100384423C/zh not_active Expired - Lifetime
- 2002-01-02 HU HU0304062A patent/HU229305B1/hu unknown
- 2002-01-02 CA CA2437524A patent/CA2437524C/en not_active Expired - Lifetime
- 2002-01-18 MY MYPI20020202A patent/MY137480A/en unknown
- 2002-01-23 TW TW091101013A patent/TWI318978B/zh not_active IP Right Cessation
- 2002-01-31 AR ARP020100336A patent/AR034292A1/es active IP Right Grant
- 2002-02-01 PE PE2002000075A patent/PE20020855A1/es not_active Application Discontinuation
-
2003
- 2003-07-21 IL IL157029A patent/IL157029A/en active IP Right Grant
- 2003-07-22 BG BG108021A patent/BG66359B1/bg unknown
- 2003-07-30 IS IS6899A patent/IS2912B/is unknown
- 2003-07-30 ZA ZA2003/05885A patent/ZA200305885B/en unknown
- 2003-08-01 NO NO20033436A patent/NO326510B1/no not_active IP Right Cessation
-
2012
- 2012-09-12 CY CY20121100828T patent/CY1113194T1/el unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2099336C1 (ru) * | 1991-04-05 | 1997-12-20 | Лабораториос Дель Др.Эстеве, С.А. | Производные бензимидазола, способ их получения и фармацевтическая композиция на их основе, обладающая антигистаминной активностью |
| WO1996011929A1 (en) * | 1994-10-12 | 1996-04-25 | Smithkline Beecham Plc | Biheteroaryl-carbonyl and carboxamide derivatives with 5ht 2c/2b antagonists activity |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4328527B2 (ja) | 置換アザインドールオキソアセチックピペラジン誘導体の組成物と抗ウイルス活性 | |
| US7354924B2 (en) | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives | |
| AU2009202361B2 (en) | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives | |
| RS60903B1 (sr) | Zaptivna etiketa i burmutica sa zaptivnom etiketom | |
| AU2002241824B2 (en) | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives | |
| HK1056698B (en) | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives | |
| AU2002241824A1 (en) | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC41 | Official registration of the transfer of exclusive right |
Effective date: 20181022 |
|
| TK4A | Correction to the publication in the bulletin (patent) |
Free format text: CORRECTION TO CHAPTER -PC4A- IN JOURNAL 30-2018 FOR INID CODE(S) D N |